Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology（2023）

引用 1|浏览6

暂无评分

摘要

The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.

查看译文

关键词

ICER,biologics,cost,omalizumab,pharmacoeconomics,severe pediatric allergic asthma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要